To access the full text documents, please follow this link: http://hdl.handle.net/2445/47024

Changes in forced expiratory volume in 1 second over time in COPD
Vestbo, Jørgen; Edwards, Lisa D.; Scanlon, Paul D.; Yates, Julie C.; Agustí García-Navarro, Àlvar; Bakke, Per; Calverley, Peter M.; Celli, Bartolome; Coxson, Harvey O.; Crim, Courtney; Lomas, David A.; MacNee, William; Miller, Bruce E.; Silverman, Edwin K.; Tal-Singer, Ruth; Wouters, Emiel; Rennard, Stephen I.
Universitat de Barcelona
Background A key feature of chronic obstructive pulmonary disease (COPD) is an accelerated rate of decline in forced expiratory volume in 1 second (FEV 1), but data on the variability and determinants of this change in patients who have established disease are scarce. Methods We analyzed the changes in FEV 1 after administration of a bronchodilator over a 3-year period in 2163 patients. A random-coefficient model was used to evaluate possible predictors of both FEV 1 levels and their changes over time. Results The mean (±SE) rate of change in FEV 1 was a decline of 33±2 ml per year, with sig - nificant variation among the patients studied. The between-patient standard deviation for the rate of decline was 59 ml per year. Over the 3-year study period, 38% of patients had an estimated decline in FEV 1 of more than 40 ml per year, 31% had a decline of 21 to 40 ml per year, 23% had a change in FEV 1 that ranged from a de - crease of 20 ml per year to an increase of 20 ml per year, and 8% had an increase of more than 20 ml per year. The mean rate of decline in FEV 1 was 21±4 ml per year greater in current smokers than in current nonsmokers, 13±4 ml per year greater in patients with emphysema than in those without emphysema, and 17±4 ml per year greater in patients with bronchodilator reversibility than in those without reversibility. Conclusions The rate of change in FEV 1 among patients with COPD is highly variable, with increased rates of decline among current smokers, patients with bronchodilator reversibility, and patients with emphysema. (Funded by GlaxoSmithKline; ECLIPSE ClinicalTrials.gov number, NCT00292552).
Malalties pulmonars obstructives cròniques
Assaigs clínics de medicaments
Broncodilatadors
Chronic obstructive pulmonary diseases
Drug testing
Bronchodilator agents
(c) Massachusetts Medical Society, 2011
Article
info:eu-repo/semantics/publishedVersion
Massachusetts Medical Society
         

Show full item record

Related documents

Other documents of the same author

Agustí García-Navarro, Àlvar; Edwards, Lisa D.; Rennard, Stephen I.; MacNee, William; Tal-Singer, Ruth; Miller, Bruce E.; Vestbo, Jørgen; Lomas, David A.; Calverley, Peter M.; Wouters, Emiel; Crim, Courtney; Yates, Julie C.; Silverman, Edwin K.; Coxson, Harvey O.; Bakke, Per; Mayer, Ruth J.; Celli, Bartolome
Agustí García-Navarro, Àlvar; Calverley, Peter M.; Celli, Bartolome; Coxson, Harvey O.; Edwards, Lisa D.; Lomas, David A.; MacNee, William; Miller, Bruce E.; Rennard, Stephen I.; Silverman, Edwin K.; Tal-Singer, Ruth; Wouters, Emiel; Yates, Julie C.; Vestbo, Jørgen
Wilke, Sarah; Jones, Paul W.; Müllerova, H.; Vestbo, Jørgen; Tal-Singer, Ruth; Franssen, Frits M.E.; Agustí García-Navarro, Àlvar; Bakke, Per; Calverley, Peter M.; Coxson, Harvey O.; Crim, Courtney; Edwards, Lisa D.; Lomas, David A.; MacNee, William; Rennard, Stephen I.; Yates, Julie C.; Wouters, Emiel; Spruit, Martijn A.
Hurst, John R.; Vestbo, Jørgen; Anzueto, Antonio; Locantore, Nicholas; Müllerova, Hana; Tal-Singer, Ruth; Miller, Bruce; Lomas, David A.; Agustí García-Navarro, Àlvar; MacNee, William; Calverley, Peter M.; Rennard, Stephen I.; Wouters, Emiel; Wedzicha, Jadwiga A.
Patel, B. D.; Coxson, H. O.; Camp, P. G.; Pillai, S. G.; Agustí García-Navarro, Àlvar; Calverley, Peter M.; Donner, C. F.; Make, B. J.; Müller, N. L.; Rennard, Stephen I.; Vestbo, Jørgen; Wouters, Emiel; Anderson, W. H.; Paré, P. D.; Levy, R. D.; Silverman, Edwin K.; Lomas, David A.
 

Coordination

 

Supporters